On the PHLPPside: Emerging roles of PHLPP phosphatases in the heart.
Authors:
Journal: Cellular signalling
Publication Type: Journal Article
Date: 2021
DOI: NIHMS1731097
ID: 34320369
Abstract
PH domain leucine-rich repeat protein phosphatase (PHLPP) is a family of enzymes made up of two isoforms (PHLPP1 and PHLPP2), whose actions modulate intracellular activity via the dephosphorylation of specific serine/threonine (Ser/Thr) residues on proteins such as Akt. Recent data generated in our lab, supported by findings from others, implicates the divergent roles of PHLPP1 and PHLPP2 in maintaining cellular homeostasis since dysregulation of these enzymes has been linked to various pathological states including cardiovascular disease, diabetes, ischemia/reperfusion injury, musculoskeletal disease, and cancer. Therefore, development of therapies to modulate specific isoforms of PHLPP could prove to be therapeutically beneficial in several diseases especially those targeting the cardiovascular system. This review is intended to provide a comprehensive summary of current literature detailing the role of the PHLPP isoforms in the development and progression of heart disease.
Chemical List
- Nuclear Proteins|||Protein Isoforms|||Proto-Oncogene Proteins c-akt|||PHLPP2 protein, human|||Phosphoprotein Phosphatases
Reference List
- Gao T, Furnari F, and Newton AC, PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell, 2005. 18(1): p. 13–24.|||Sierecki E and Newton AC, Biochemical characterization of the phosphatase domain of the tumor suppressor PH domain leucine-rich repeat protein phosphatase. Biochemistry, 2014. 53(24): p. 3971–81.|||Kamada R, et al., Metal-dependent Ser/Thr protein phosphatase PPM family: Evolution, structures, diseases and inhibitors. Pharmacol Ther, 2020. 215: p. 107622.|||Brognard J, et al., PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell, 2007. 25(6): p. 917–31.|||Brognard J and Newton AC, PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab, 2008. 19(6): p. 223–30.|||Kawashima AT, et al., The PHLPP1 N-Terminal Extension is a Mitotic Cdk1 Substrate and Controls an Interactome Switch. Mol Cell Biol, 2021.|||Cohen Katsenelson K, et al., PHLPP1 counter-regulates STAT1-mediated inflammatory signaling. eLife, 2019. 8: p. e48609.|||Shima F, et al., Association of yeast adenylyl cyclase with cyclase-associated protein CAP forms a second Ras-binding site which mediates its Ras-dependent activation. Mol Cell Biol, 2000. 20(1): p. 26–33.|||Miyamoto S, et al., PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ Res, 2010. 107(4): p. 476–84.|||Gao T, Brognard J, and Newton AC, The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem, 2008. 283(10): p. 6300–11.|||Moc C, et al., Physiological activation of Akt by PHLPP1 deletion protects against pathological hypertrophy. Cardiovasc Res, 2015. 105(2): p. 160–70.|||Chen B, et al., PHLPP1 gene deletion protects the brain from ischemic injury. J Cereb Blood Flow Metab, 2013. 33(2): p. 196–204.|||Qiao M, et al., Mst1 is an interacting protein that mediates PHLPPs’ induced apoptosis. Mol Cell, 2010. 38(4): p. 512–23.|||Liu J, Stevens PD, and Gao T, mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J Biol Chem, 2011. 286(8): p. 6510–20.|||Baffi TR, et al., Protein Kinase C Quality Control by Phosphatase PHLPP1 Unveils Loss-of-Function Mechanism in Cancer. Mol Cell, 2019. 74(2): p. 378–392.e5.|||Braz JC, et al., PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med, 2004. 10(3): p. 248–54.|||Marrocco V, et al., PKC and PKN in heart disease. J Mol Cell Cardiol, 2019. 128: p. 212–226.|||Shimizu K, et al., Proteolytic degradation of SCOP in the hippocampus contributes to activation of MAP kinase and memory. Cell, 2007. 128(6): p. 1219–29.|||Shimizu K, Mackenzie SM, and Storm DR, SCOP/PHLPP and its functional role in the brain. Mol Biosyst, 2010. 6(1): p. 38–43.|||Reyes G, et al., Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output. Proc Natl Acad Sci U S A, 2014. 111(38): p. E3957–65.|||Agarwal NK, et al., PHLPP2 suppresses the NF-kappaB pathway by inactivating IKKbeta kinase. Oncotarget, 2014. 5(3): p. 815–23.|||Tang B, et al., Tumor necrosis factor-alpha upregulated PHLPP1 through activating nuclear factor-kappa B during myocardial ischemia/reperfusion. Life sciences, 2018. 207: p. 355–363.|||Wen YA, et al., Loss of PHLPP protects against colitis by inhibiting intestinal epithelial cell apoptosis. Biochim Biophys Acta, 2015. 1852(10 Pt A): p. 2013–23.|||Huang J, et al., Endothelial Scaffolding Protein ENH (Enigma Homolog Protein) Promotes PHLPP2 (Pleckstrin Homology Domain and Leucine-Rich Repeat Protein Phosphatase 2)-Mediated Dephosphorylation of AKT1 and eNOS (Endothelial NO Synthase) Promoting Vascular Remodeling. Arterioscler Thromb Vasc Biol, 2020. 40(7): p. 1705–1721.|||Pei H, et al., FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell, 2009. 16(3): p. 259–66.|||Pereira MJ, et al., FKBP5 expression in human adipose tissue increases following dexamethasone exposure and is associated with insulin resistance. Metabolism, 2014. 63(9): p. 1198–208.|||Molina JR, et al., PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene, 2012. 31(10): p. 1264–1274.|||Li Y, et al., Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. Diabetes, 2011. 60(11): p. 2985–94.|||Boczonadi V, et al., Scrib:Rac1 interactions are required for the morphogenesis of the ventricular myocardium. Cardiovasc Res, 2014. 104(1): p. 103–15.|||Arias E, et al., Lysosomal mTORC2/PHLPP1/Akt Regulate Chaperone-Mediated Autophagy. Mol Cell, 2015. 59(2): p. 270–84.|||Wang P, et al., Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. Mol Cell, 2014. 54(3): p. 378–91.|||Amin EM, et al., WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell, 2011. 20(6): p. 768–80.|||van Gastel J, et al., β-Arrestin Based Receptor Signaling Paradigms: Potential Therapeutic Targets for Complex Age-Related Disorders. Front Pharmacol, 2018. 9: p. 1369.|||Crotty TM, et al., Diacylglycerol kinase δ modulates Akt phosphorylation through pleckstrin homology domain leucine-rich repeat protein phosphatase 2 (PHLPP2). J Biol Chem, 2013. 288(3): p. 1439–47.|||Noma T, et al., Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest, 2007. 117(9): p. 2445–58.|||Tilley DG, et al., beta-Arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. J Biol Chem, 2009. 284(30): p. 20375–86.|||Warfel NA, et al., Mislocalization of the E3 ligase, beta-transducin repeat-containing protein 1 (beta-TrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt. J Biol Chem, 2011. 286(22): p. 19777–88.|||Xing Y, et al., Mutual inhibition of insulin signaling and PHLPP-1 determines cardioprotective efficiency of Akt in aged heart. Aging (Albany NY), 2016. 8(5): p. 873–88.|||Wang Y, et al., A molecular brake controls the magnitude of long-term potentiation. Nat Commun, 2014. 5: p. 3051.|||Zheng D, et al., Targeted inhibition of calpain in mitochondria alleviates oxidative stress-induced myocardial injury. Acta Pharmacol Sin, 2020.|||Gangula NR and Maddika S, WD repeat protein WDR48 in complex with deubiquitinase USP12 suppresses Akt-dependent cell survival signaling by stabilizing PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1). J Biol Chem, 2013. 288(48): p. 34545–54.|||Zhang X, et al., FANCI is a negative regulator of Akt activation. Cell Cycle, 2016. 15(8): p. 1134–43.|||Li X, et al., The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer. Oncogene, 2013. 32(4): p. 471–8.|||Baffi TR, Cohen-Katsenelson K, and Newton AC, PHLPPing the Script: Emerging Roles of PHLPP Phosphatases in Cell Signaling. Annu Rev Pharmacol Toxicol, 2021. 61: p. 723–743.|||Mussnich P, et al., MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets, 2015. 19(8): p. 1017–26.|||Chen X, et al., Analysis of the function of microRNA-375 in humans using bioinformatics. Biomed Rep, 2017. 6(5): p. 561–566.|||Liang Y, et al., Identification and prediction of novel non-coding and coding RNA-associated competing endogenous RNA networks in colorectal cancer. World J Gastroenterol, 2018. 24(46): p. 5259–5270.|||Ali Sheikh MS, Overexpression of miR-375 Protects Cardiomyocyte Injury following Hypoxic-Reoxygenation Injury. Oxid Med Cell Longev, 2020. 2020: p. 7164069.|||Garikipati VN, et al., Negative Regulation of miR-375 by Interleukin-10 Enhances Bone Marrow-Derived Progenitor Cell-Mediated Myocardial Repair and Function After Myocardial Infarction. Stem Cells, 2015. 33(12): p. 3519–29.|||Miyamoto S, Murphy AN, and Brown JH, Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ, 2008. 15(3): p. 521–9.|||Gao MH, et al., Activation of PH-domain leucine-rich protein phosphatase 2 (PHLPP2) by agonist stimulation in cardiac myocytes expressing adenylyl cyclase type 6. Biochem Biophys Res Commun, 2009. 384(2): p. 193–8.|||Yeh S-T, et al., PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2) regulates G-protein-coupled receptor kinase 5 (GRK5)-induced cardiac hypertrophy in vitro. The Journal of biological chemistry, 2018. 293(21): p. 8056–8064.|||Purcell NH, et al., Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A, 2007. 104(35): p. 14074–9.|||Grzechnik AT and Newton AC, PHLPPing through history: a decade in the life of PHLPP phosphatases. Biochem Soc Trans, 2016. 44(6): p. 1675–1682.|||Lips DJ, et al., MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation, 2004. 109(16): p. 1938–41.|||DeBosch B, et al., Akt1 is required for physiological cardiac growth. Circulation, 2006. 113(17): p. 2097–104.|||Shiojima I, et al., Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest, 2005. 115(8): p. 2108–18.|||Shiojima I and Walsh K, Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev, 2006. 20(24): p. 3347–65.|||Traynham CJ, Hullmann J, and Koch WJ, “Canonical and non-canonical actions of GRK5 in the heart”. J Mol Cell Cardiol, 2016. 92: p. 196–202.|||Martini JS, et al., Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A, 2008. 105(34): p. 12457–62.|||Gold JI, et al., Nuclear translocation of cardiac G protein-Coupled Receptor kinase 5 downstream of select Gq-activating hypertrophic ligands is a calmodulin-dependent process. PLoS One, 2013. 8(3): p. e57324.|||Karar J and Maity A, PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci, 2011. 4: p. 51.|||Flanagan MF, et al., Myocardial angiogenesis and coronary perfusion in left ventricular pressure-overload hypertrophy in the young lamb. Evidence for inhibition with chronic protamine administration. Circ Res, 1991. 68(5): p. 1458–70.|||Anversa P, et al., Morphometry of exercise-induced right ventricular hypertrophy in the rat. Circ Res, 1983. 52(1): p. 57–64.|||Münzel T and Daiber A, Novel Concept for the Regulation of eNOS (Endothelial Nitric Oxide Synthase) Activity: Inhibitory Effects of the Enigma Homolog Protein and the PHLPP (Pleckstrin Homology Domain and Leucine-Rich Repeat Protein Phosphatase)-2 on Akt (Protein Kinase B)-Dependent Nitric Oxide Synthase Activation. Arterioscler Thromb Vasc Biol, 2020. 40(7): p. 1608–1610.|||Benjamin EJ, et al., Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation, 2019. 139(10): p. e56–e528.|||Bulluck H, Yellon DM, and Hausenloy DJ, Reducing myocardial infarct size: challenges and future opportunities. Heart, 2016. 102(5): p. 341–8.|||Mockridge JW, Marber MS, and Heads RJ, Activation of Akt during simulated ischemia/reperfusion in cardiac myocytes. Biochem Biophys Res Commun, 2000. 270(3): p. 947–52.|||Randhawa PK, et al., Conditioning-induced cardioprotection: Aging as a confounding factor. Korean J Physiol Pharmacol, 2018. 22(5): p. 467–479.|||Jin A, et al., PHLPP2 downregulation protects cardiomyocytes against hypoxia-induced injury through reinforcing Nrf2/ARE antioxidant signaling. Chemico-biological interactions, 2019. 314: p. 108848–108848.|||Zhang C, et al., Phlpp1 is associated with human intervertebral disc degeneration and its deficiency promotes healing after needle puncture injury in mice. Cell Death Dis, 2019. 10(10): p. 754.|||Bradley EW, Carpio LR, and Westendorf JJ, Histone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression in chondrocytes to suppress Akt signaling and matrix secretion. J Biol Chem, 2013.|||Bradley EW, et al., Deletion of the PH-domain and Leucine-rich Repeat Protein Phosphatase 1 (Phlpp1) Increases Fibroblast Growth Factor (Fgf) 18 Expression and Promotes Chondrocyte Proliferation. J Biol Chem, 2015. 290(26): p. 16272–80.|||Weaver SR, et al., Pleckstrin homology (PH) domain and leucine rich repeat phosphatase 1 (Phlpp1) suppresses parathyroid hormone receptor 1 (Pth1r) expression and signaling during bone growth. J Bone Miner Res, 2021.|||Bradley EW, et al., Phlpp1 facilitates post-traumatic osteoarthritis and is induced by inflammation and promoter demethylation in human osteoarthritis. Osteoarthritis Cartilage, 2016. 24(6): p. 1021–8.|||Castillejo Becerra CM, et al., DNA methylation and FoxO3a regulate PHLPP1 expression in chondrocytes. J Cell Biochem, 2018. 119(9): p. 7470–7478.|||Andreozzi F, et al., Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistance. Diabetologia, 2011. 54(7): p. 1879–87.|||Behera S, et al., ERK1/2 activated PHLPP1 induces skeletal muscle ER stress through the inhibition of a novel substrate AMPK. Biochim Biophys Acta Mol Basis Dis, 2018. 1864(5 Pt A): p. 1702–1716.|||Liu Y, et al., Deleting both PHLPP1 and CANP1 rescues impairments in long-term potentiation and learning in both single knockout mice. Learn Mem, 2016. 23(8): p. 399–404.|||Jackson TC, et al., PHLPP1 splice variants differentially regulate AKT and PKCalpha signaling in hippocampal neurons: characterization of PHLPP proteins in the adult hippocampus. J Neurochem, 2010. 115(4): p. 941–55.|||Jackson TC, et al., Pharmacological inhibition of pleckstrin homology domain leucine-rich repeat protein phosphatase is neuroprotective: differential effects on astrocytes. J Pharmacol Exp Ther, 2013. 347(2): p. 516–28.|||Jackson TC, et al., Acute Physiology and Neurologic Outcomes after Brain Injury in SCOP/PHLPP1 KO Mice. Sci Rep, 2018. 8(1): p. 7158.|||Wei XE, et al., Assembly of the FKBP51-PHLPP2-AKT signaling complex in cerebral ischemia/reperfusion injury in rats. Brain Res, 2014. 1566: p. 60–8.|||O’Neill AK, Niederst MJ, and Newton AC, Suppression of survival signalling pathways by the phosphatase PHLPP. Febs J, 2012.|||Smith AJ, et al., PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells. Oncotarget, 2016. 7(7): p. 7801–15.|||Qin Y, et al., SNORA74B gene silencing inhibits gallbladder cancer cells by inducing PHLPP and suppressing Akt/mTOR signaling. Oncotarget, 2017. 8(12): p. 19980–19996.|||Teng DC, et al., Role of PHLPP1 in inflammation response: Its loss contributes to gliomas development and progression. Int Immunopharmacol, 2016. 34: p. 229–234.|||Liu J, et al., Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene, 2009. 28(7): p. 994–1004.|||Chen M, et al., Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell, 2011. 20(2): p. 173–86.|||Nowak DG, et al., MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discov, 2015. 5(6): p. 636–51.|||Nowak DG, et al., The PHLPP2 phosphatase is a druggable driver of prostate cancer progression. J Cell Biol, 2019. 218(6): p. 1943–1957.|||Sierecki E, et al., Discovery of small molecule inhibitors of the PH domain leucine-rich repeat protein phosphatase (PHLPP) by chemical and virtual screening. J Med Chem, 2010. 53(19): p. 6899–911.